Clinical Trial Detail

NCT ID NCT02143635
Title Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

myelodysplastic/myeloproliferative neoplasm

acute myeloid leukemia

acute lymphoblastic leukemia

Advanced Solid Tumor

Therapies

HDM201

Age Groups: adult

No variant requirements are available.